In the trial, the safety and efficacy of lenvatinib in combination with everolimus (arm A), or pembrolizumab (arm B), versus sunitinib (arm C) were compared as first-line treatment in patients with advanced RCC. Around 1050 patients were enrolled to the trial and they were randomised to 1 of the 3 treatment arms.

Read more in OncLive here